Downloading...
Download

DD

$SELB Beats Earnings by .10/Phase 2 Results/Cash into 2020Phase 2 head-to-head (COMPARE) clinical trial of SEL-212 vs. KRYSTEXXA® to begin in 1Q19, interim six-month data expected in 4Q19 Collaboration with CureCN projected to dose first patient with combination of ImmTOR + AAV gene therapy candidate in 2H19 Company raises $33M in gross offering proceeds and $31.3M in net proceeds in 1Q19, cash runway into 1Q20 “During 2018 we laid a strong groundwork for a year of execution in 2019. We kicked off the year by streamlining the company through a corporate restructuring, which is projected to cut our cash burn rate by 19%. We then completed an equity fundraise of approximately $33 million in gross proceeds and $31.3 million in net proceeds, and anticipate reporting key milestones for both our chronic refractory gout and gene therapy programs. We continue to believe that our lead program, SEL-212, has the potential to address several unmet needs in chronic refractory gout patients, including sustained serum uric acid reduction, reduced painful flares and once monthly dosing, and we look forward to initiating the planned six-month head-to-head (COMPARE) clinical trial against Krystexxa this month,” said Carsten Brunn, Ph.D., President and CEO of Selecta. “We also look forward to further advancing our ImmTOR + AAV gene therapy combination product candidate in Crigler-Najjar Syndrome in collaboration with CureCN in the second half of the year and identifying other ways to advance our ImmTOR platform and grow our strategic partnerships.” Effective December 1, 2018, Carsten Brunn, Ph.D., assumed the role of President and CEO of Selecta, following his previous position as President of Pharmaceuticals for the Americas Region and member of the Global Pharmaceutical Executive Committee at Bayer. Reported Phase 2 Data: Selecta has reported data from its Phase 2 trial showing that 66% of evaluable patients (21/32), maintained serum uric acid (sUA) levels of <6mg/dL after five oncemonthly treatments of SEL-212 at doses of 0.1 or 0.15 mg/kg of ImmTOR in combination with 0.2mg/kg of pegadricase. Furthermore, reduced total urate burden and lowered flare rates and severity were observed in the Phase 2 clinical trial, and SEL-212 continued to be generally well tolerated. Collaboration with CureCN Consortium Projected to Dose First Patient in 2H19: In September 2018, Selecta announced a collaboration with CureCN, a European consortium, for an ImmTOR+AAV gene therapy combination product candidate in Crigler-Najjar Syndrome, building upon preclinical work that was published together with Genethon in Nature Communications in October 2018. Selecta expects CureCN to initiate preclinical toxicology studies in the first half of 2019 and for the combination product candidate to enter the clinic in the second half of 2019. Selecta expects to initiate a Phase 2 head-to-head (COMPARE) clinical trial of SEL-212, compared to the current FDA-approved uricase therapy, Krystexxa, in the first quarter of 2019. An interim six-month data readout is projected for the fourth quarter of 2019, with a full statistical data analysis expected in the first quarter of 2020. The results of the COMPARE trial are expected to inform the design of the planned Phase 3 clinical trial of SEL-212, which the company plans to initiate in the fourth quarter of 2019. Cash Position: Selecta had $37.7 million in cash, cash equivalents and restricted cash as of December 31, 2018, which compares to cash, cash equivalents and short-term investments of $50.5 million at September 30, 2018. The company currently has a cash runway into the first quarter of 2020, which includes proceeds net of underwriting discounts and commissions of $31.3 million from the company’s recent follow-on offering in January 2019. Corporate Restructuring Completed in January 2019: Selecta completed a corporate restructuring that reduced the company’s workforce by 36 percent as of January 3, 2019. This reduction, coupled with a reprioritization of the company’s pipeline programs, is projected to reduce the yearly cash burn by 19 percent. Successfully Completed a $33.3 Million Public Offering; Providing Cash Runway into 1Q20: In January 2019, Selecta completed an underwritten public offering of 22,188,706 shares of its common stock, at a price to public of $1.50 per share, resulting in net proceeds to Selecta of $31.3 million, after deducting underwriting discounts and commissions.
SLong
by StockGuild
YY - Continuation patternYY is a Chinese video social media platform, most prominently featuring video streaming. It has a massive user base (although many outside of China have never heard of it) with over 300M users and is rapidly growing. After the most recent earnings report, price of the stock went from $140 to as low as $115 - and as far as I can tell, there was no "fatal" bad news. This dip is a good opportunity to buy in. Looking at the chart, we can see that YY has been on a long bull run since the start of 2017. With the recent price action, it appears to be forming a flag - which is a continuation pattern. We should see the price test $135-$140 again very soon, and if broken, we may see another strong bull run leading up to the next earnings report (May 8). If it cannot break through the upper bound (or even breaks down), things will get a bit more interesting..
Y
by dvdgege5
2
Du Pont, new bearish correctionAn upward trend, which used to be a prevailing one is close to a revearsal. To prove this idea we use Chaikin Oscillator. It proves that the tendency is one step from a turn. The previous pick on the oscillator graph compared with the curent one used to be higher while the previous pick on the main graph is lower at the same time. Moreover, the fall of two recent days is connected with the resistance line, which had been reached. I suppose that it is an alert for short trading. The price has a fall potential of 2,5%. However, we should take into consideration the fact that tomorrow the company is going to publish its financials. If we face positive figures, than the stocks might rise. I believe if an upward trend appeares, it won't continue for a long period if time. Afterward we will see a downstream.
NYSE:DDShort
by MaxLev
DD analysis Elliott Wave, along with company analysisDD has recently broken out, and seems to be in the process of it's own 3rd wave movement upwards. According to GuruFocus, the latest major guru trades have been buys with no sells. So the stock likely has some further upside potential thanks to the large shareholdings by certain major investors other than insiders. This would give further credence to the notion that the stock is currently going through a brand new 3rd wave of it's own, which when compared to the greater Elliott Wave analysis, would put this as another large 3rd wave after the first 1-2-3-4-5 and A-B-C completed their own 2 waves. The company is also completing a merger with Dow Chemicals, forming a new company DowDuPont. However, there is uncertainty about the potential of this merger as there are anti-trust issues, and economic questions in regards to the profitability of this new company. (source: Wikipedia) The stock could possibly climb through another 3rd wave, and then a 4th wave down before completing a 5th wave peak within the future. It will be a goal to find a possible entry for this trade, initially as a day trade for the current breakout, and then later it may turn into an intra-day swing trade by locking in some profits, and letting the rest of the shares ride with potential for pyramiding later on with larger timeframes.
NYSE:DDLong
by Yqztv09
$AMEL On Bounce WatchOn the hunt for the next hot sector? Will the Pot sector return to glory? Well the lithium sector could become the front runner with the right catalyst. Tesla is on the move to build new factories and add in a rise on oil and the lithium stocks could get dragged into the spotlight. Aside from that speculation; $AMEL is a former runner that is starting to form a nice base at the .0024 area. I will be watching for a break above the shown downtrend line with some volume and we could have a nice bounce. Ok, now its time to get back to my DD on $TSLA and lithium OTC stocks. Good Luck!
ALong
by AcetheGap11
1